Clinical Trial

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Study acronym: RAMP 201
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Protocol Amendment History 70 amendments
This ClinicalTrials.gov record has been amended 70 times since 2020-11-06; most recent amendment 2025-01-26.
Status change: Recruiting → Active, Not Recruiting 2024-03-08
Status change: Not Yet Recruiting → Recruiting 2020-12-31
Trial Details
NCT Number NCT04625270
Lead Sponsor Verastem, Inc.
Collaborators: European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Conditions Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
Enrollment 225 participants
Start Date 2020-12-21
Primary Completion 2024-11-15 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-01-29